Home/Filings/4/0001209191-23-049977
4//SEC Filing

Alles Mark J 4

Accession 0001209191-23-049977

CIK 0001556263other

Filed

Sep 18, 8:00 PM ET

Accepted

Sep 19, 4:47 PM ET

Size

7.6 KB

Accession

0001209191-23-049977

Insider Transaction Report

Form 4
Period: 2023-09-16
Alles Mark J
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2023-09-16+2,6663,666 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-09-162,6665,334 total
    Common Stock (2,666 underlying)
Footnotes (4)
  • [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
  • [F2]On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
  • [F3]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
  • [F4]Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother

Related Parties

1
  • filerCIK 0001538897

Filing Metadata

Form type
4
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 4:47 PM ET
Size
7.6 KB